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Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase family whose members
have been implicated in tumor suppression in many cancer models. In many cancers, loss
of PP2A activity has been associated with tumorigenesis and drug resistance. Loss of
PP2A results in failure to turn off survival signaling cascades that drive drug resistance
such as those regulated by protein kinase B. PP2A is responsible for modulating func-
tion and controlling expression of tumor suppressors such as p53 and oncogenes such as
BCL2 and MYC. Thus, PP2A has diverse functions regulating cell survival. The importance
of microRNAs (miRs) is emerging in cancer biology. A role for miR regulation of PP2A is not
well understood; however, recent studies suggest a number of clinically significant miRs
such as miR-155 and miR-19 may include PP2A targets. We have recently found that a
PP2A B subunit (B55α) can regulate a number of miRs in acute myeloid leukemia cells.The
identification of a miR/PP2A axis represents a novel regulatory pathway in cellular home-
ostasis.The ability of miRs to suppress specific PP2A targets and for PP2A to control such
miRs can add an extra level of control in signaling that could be used as a rheostat for many
signaling cascades that maintain cellular homeostasis. As such, loss of PP2A or expression
of miRs relevant for PP2A function could promote tumorigenesis or at least result in drug
resistance. In this review, we will cover the current state of miR regulation of PP2A with
a focus on leukemia. We will also briefly discuss what is known of PP2A regulation of miR
expression.
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INTRODUCTION
The cellular signaling pathways that control cellular homeostasis
are complex and involve a diversity of activators and suppressors.
As signal transduction is a dynamic process, the elements involved
in turning off kinases are just as important as those that activate
the signaling cascade. Protein phosphatase 2A (PP2A) is thought
of as a global negative regulator of signaling. In reality, PP2A is
not a single enzyme but rather a family of protein phosphatases
that vary in the substrates they target, in the cell types where they
are expressed, in the cellular compartments where they are found,
and how they are regulated (1–5). The diversity of function lies
in the PP2A structure. The enzyme is a heterotrimer that consists
of a catalytic core that is responsible for the dephosphorylation
event as well as a regulatory subunit that controls substrate speci-
ficity and cellular localization. The catalytic core is comprised of
the catalytic C subunit which has two isoforms [PPP2RCA aka
Cα and PPP2CB aka Cβ; Ref. (6)] and the scaffold A subunit
which also has two isoforms [PPP2R1A aka Aα and PPP2R1B aka
Aβ; Ref. (7)]. Each isoform is located on a separate chromosome
in humans. Though for both A and C subunits the isoforms are
>80% homologous by protein sequence, there are distinct differ-
ences between each isoform (6, 7). Thus, there are four different
catalytic cores that could influence PP2A activity. The B regulatory
subunit determines the substrate specificity and cellular localiza-
tion of the resulting PP2A isoform. There are at present at least
17 different B subunit proteins that are members of at least three
families [i.e., PR55/B; PR61/B′; and PR72/B′′; Ref. (1–4)]. PP2A is
an obligate heterotrimer so monomeric B subunits are degraded
(8, 9). Modification of components of the catalytic core influ-
ences binding affinity of the B subunits and thus modulates PP2A
function (1). Furthermore, post-translational modification of B
subunits can affect sub-cellular localization of the PP2A isoform
and influence,which proteins are targeted. We have found the B56α
subunit (PPP2R5A) when phosphorylated at serine 28 re-localizes
from the nucleus to the mitochondria (10). While nuclear B56α
likely supports survival signaling, in the mitochondria the B sub-
unit dephosphorylates and inactivates BCL2 to support pro-death
function. Depending on phosphorylation status, the PP2A iso-
form with B56α can either support or impede survival (10). Thus,
cell growth and survival of any given cell depends on it having the
appropriate PP2A isoform(s) in place (with the required subunit
modifications) to regulate the signaling cascades that are critical
for its cell type. In cell that fails to express the PP2A isoforms
required for its cell type, it is plausible that the result would be
aberrant activation of any number of signal cascades that promotes
tumorigenesis or supports drug resistance in the malignant cells.
Suppression of the PP2A family to promote global activation
of cellular kinases can be achieved by targeting the catalytic core.
Mechanisms include post-translational modification to inactivate
protein phosphatase function [e.g., phosphorylation or methy-
lation of the catalytic subunit; Ref. (11–13)], involvement of
viral inhibitors like the SV40 small T antigen (14–17), or acti-
vation of cellular inhibitors such as SET or CIP2A, the former
of which is induced by BCR–ABL in chronic myeloid leukemia
www.frontiersin.org February 2015 | Volume 5 | Article 43 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ruvolo PP2A/miR axis in leukemia
[CML; (18–23)]. PP2A can be inactivated by genetic means as
well. Mutation of PP2A subunits have been reported with the best
characterized so far being those found in the Aα and Aβ isoforms
(24, 25). Also, chromosome deletion or translocation containing
PP2A subunits have been identified. The 5q deletion can include
catalytic Cα subunit and loss of this PP2A subunit has been sug-
gested to be important in myelodysplastic syndrome (MDS) as
determined by the List Laboratory (26, 27). The topics of genetic
and post-translational control of PP2A and role of SET and CIP2A
are covered elsewhere in this Research Topics series. This review
will focus on the emerging role of microRNAs (miRs) to regulate
PP2A and will also include how at least one PP2A isoform has
been shown to regulate miR expression. The interplay between
the protein phosphatases and miRs suggest an elaborate feedback
mechanism exists to serve as an extra level of control for signal
transduction.
PP2A IN ROLE IN LEUKEMIA
We have some knowledge of PP2A role in CML and Philadelphia
chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
thanks in large part to the work of the Perrotti group in their stud-
ies on BCR–ABL regulation of PP2A in these diseases (18–23). In
CML, activation of PP2A is an important part of the mechanism
of killing the malignant cells. Furthermore, activation of PP2A by
FTY-720 or like drugs has anti-leukemic properties including for
acute myeloid leukemia (AML) cells (18–21). Still, little is known
about the role of PP2A in leukemia and other hematologic malig-
nancies at present. AML remains a highly fatal disease despite our
best efforts to develop novel therapies. Strategies to design tai-
lored therapy have been in vogue but a problem arises that AML
patients with the poorest outcome likely have multiple survival
kinase cascades activated. Kornblau and colleagues reported that
simultaneous activation of protein kinase B (AKT), protein kinase
Cα (PKCα), and extracellular signal regulated kinase (ERK) is very
detrimental to the AML patient (28). Up to 80% of AML patients
have phosphorylated AKT and activation of the kinase is associ-
ated with poor prognosis (29–31). Mutations of upstream AKT
signaling activators such as Fms-related tyrosine kinase (FLT3), c-
KIT, or RAS are found in AML patients (29–31). Targeting mutated
enzymes like FLT3 could suppress the aberrant induction of AKT.
Though mutation of receptor tyrosine kinases (RTK) like FLT3 has
been suggested to be essential for AML, the recent report in Cell
from Welch and colleagues on genomic screening of mutations in
AML indicate that less than half of AML patients have a RTK muta-
tion suggesting that other mechanisms are necessary to activate
leukemic signaling pathways (32). Gallay and colleagues deter-
mined that reduced PP2A activity was associated with increased
phosphorylation of AKT in AML patient samples (33). The Odero
Laboratory in Spain has done extensive studies of PP2A and SET
in AML (34–36). They determined that elevated SETBP1 (which
stabilizes SET and supports suppression of PP2A) was associated
with poor survival outcome in AML patients (34). Like Gally et al.
(33), they found that PP2A activity was reduced in AML patient
samples and suppressed activity of the protein phosphatase likely
involved multiple mechanisms including phosphorylation of the C
subunit, inhibition by SET or CIP2A, or dysregulation of subunit
expression (35). Our own work has determined that suppressed
expression of a specific B subunit,B555α, is critical in AML patients
resulting in shorter remission duration and increased activation
of AKT and PKC α (37, 38). PP2A in acute lymphoid leukemia has
not been studied as well in the clinical setting but pre-clinical
models suggest that the protein phosphatase family is impor-
tant in regulation of apoptosis via BCL2 and NOTCH pathways
(10, 39–41).
THE ROLE OF miRs IN LEUKEMIA
The discovery of miRs was made in C. elegans in 1993 when the
lin-4 gene product was identified as a RNA product that was com-
plimentary to the lin-14 gene (42). In 2002, George Calin with
Carlo Croce discovered that the 13q14 deletions found in chronic
lymphoblastic leukemia (CLL) resulted in loss of miR-15 and miR-
16, resulting in over expression of anti-apoptotic proteins such as
BCL2 (43). An explosion of studies have occurred linking expres-
sion of a wide variety of miRs to various cancers [reviewed in Ref.
(44–46)]. The role of miRs in cancer has proven to be complex.
miRs can either act as tumor suppressors or tumor promoters
depending on their targets (44–46). For instance, the let-7 family
of miRs tends to act as tumor suppressors by targeting a number
of pro-survival molecules such as RAS, BCL-XL, and MYC (46–
49). Recent work from the Andreeff Laboratory identified a novel
mechanism for the chemokine receptor CXCR4 in the regulation
of let-7 (50). In leukemia, a number of miRs have been identified
that are important in leukemia cell biology and drug resistance
(51–58). Some of these miRs, like miR-15, are tumor suppressors
that are reduced or lost in cancer cells. miRs play a critical role
in cell differentiation. There has been intensive investigation of
miR-155 in a variety of leukemias (59–63). The Baltimore group
found that overexpression of miR-155 in murine hematopoietic
stem cells resulted in altered hematopoiesis skewing toward gran-
ulocyte/macrophage population and mice exhibited features of
myeloid neoplasia (59). Importantly, the miR was found to target
a number of genes that regulate myeloid differentiation includ-
ing PU.1. In that and subsequent studies, miR-155 was found to
be associated with poor survival outcome in AML patients (59,
61, 62). miR-181 family members, on the other hand, support
myeloid differentiation by targeting homeobox (HOX) genes such
as HOXA9 and other myeloid regulatory genes (64, 65). While still
the role of many miRs in leukemia remains unknown, a grow-
ing number of these ncRNAs are clearly important in leukemia
biology and may be considered for targeting in future therapeutic
strategies.
miR REGULATION OF PP2A SUBUNITS
The B subunit regulation mechanism best studied is the one
involving proteolytic control. Alternative mechanisms could
include regulation of PP2A genes by transcription factors or miRs.
A comprehensive study of the A α gene was done by Chen and col-
leagues and identified a number of transcription factors including
SP-1 that control expression of the scaffold gene (66). In hepatocel-
lular carcinoma (HCC), a single nucleotide polymorphism (SNP)
mutation in the PP2A A α promoter affects regulation by NF κB
(67). The study found that individuals from Southern China with
the SNP (rs11453459) were less likely to develop HCC as these
individuals exhibited greater expression of the PP2A scaffold gene
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mediated by NF κB (67). Other examples of gene regulation of
PP2A subunits include Ikaros suppression of transcription of the
C α subunit (68). Unfortunately, little is known of how PP2A B
subunit genes are transcribed.
There is an ongoing effort to characterize the regulation of
PP2A subunit gene expression by miRs (69–80). miRs that have
been identified as suppressors of PP2A subunit expression are
listed in Table 1 and depicted in Figure 1. Also included in Table 1
and Figure 1 are miRs that have been found to target SET and
CIP2A as suppression of these PP2A inhibitors would allow for
full and potent PP2A activity (81, 82). Regulation of B55α by miR-
222 may be important in leukemia as this miR is elevated in MDS
patients and the levels of the miR were even higher in patients
that progressed to AML (58). Effects on differentiation may be
important as many miRs including miR-222 regulate myeloid dif-
ferentiation (83–86). In addition, miR-222 has been found to be
overexpressed in some groups of AML patients and CLL patients
with refractory disease (56, 87). NOTCH regulation of miR-19 is
critical for T-ALL leukemogenesis and one of the critical targets
is B56ε (77). Suppression of B56ε has been shown to be impor-
tant in AML (36), though the significance of miR-19 in AML has
yet to be determined. A lymphoma study revealed that miR-135
targets include B56γ (80). This B subunit is a regulator of p53
and mutations of B56γ have been identified in a number of solid
tumor derived cell lines (88). While it is not known if miR-135b is
important in leukemia, the miR has been shown to be up-regulated
during megakaryocyte differentiation, so the miR plays a role in
the biology of at least some hematopoietic cells (85). A greater
understanding of the role for miRs in regulating PP2A will be
vital to further our understanding of signal transduction control
in leukemia and other cancers.
Table 1 | List of miRs reported that regulate PP2A subunit or
regulators.
PP2A subunit
or regulator
miR
identified
Cancer or disease
involved
Reference
Cα (PPP2CA) miR-520h Breast cancer (69, 70)
Cervical cancer
Aβ (PPP2R1B) miR-200c Esophageal cancer (71)
B55α (PPP2R2A) miR-222 Hepatocellular carcinoma (72)
B55α (PPP2R2A) miR-222 Lung cancer (73)
B55α (PPP2R2A) miR-31 Lung cancer (74)
B56α (PPP2R5A) miR-1 Heart disease (75)
B56α (PPP2R5A) miR-155 Infection (macrophage
response to bacteria)
(76)
B56ε (PPP2R5E) miR-19a Acute lymphoblastic
leukemia
(77, 78)
B56ε (PPP2R5E) miR-23a Gastric cancer (79)
B56γ (PPP2R5C) miR-135 Lymphoma (80)
SET miR-199b Choriocarcinoma (81)
CIP2A miR-375 Oral cancer (82)
Listed are reported miRs that target the PP2A catalytic core subunits A and C,
various regulatory B subunits, and cellular inhibitors SET and CIP2A. Cancer or
disease state associated with each report is listed.
NOVEL FEEDBACK LOOPS FOR SIGNAL TRANSDUCTION:
POSSIBLE ROLE FOR miRs AND PP2A
It has been demonstrated that miR-29a is critical for myeloid dif-
ferentiation and the miR has been shown to be reduced in AML
(88, 89). Gong and colleagues recently identified a feedback loop
involving the miR-29 family members, AKT2, and MYC (88). The
authors found that miR-29 targets AKT which could contribute to
the miR’s tumor suppressor activity in AML. Consentient with a
role for MYC as a negative regulator of miR-29a, over expression of
MYC in AML-derived cell lines resulted in suppression of miR-29a
with induction of AKT2 expression while introduction of miR-29a
into cells blocked MYC expression and AKT2 levels were reduced.
AKT regulation of MYC is likely via suppression of AKT which reg-
ulates MYC proteolysis. However, AKT has been shown to support
expression of the PP2A B subunit (i.e., B56α) that negatively reg-
ulates MYC (10, 90, 91). Thus, an elaborate feedback mechanism
to regulate AKT signaling could be mediated by interplay between
miR-29a, MYC, and PP2A. To further complicate matters, miR-155
has been identified as an important tumor promoter in AML, high
risk MDS, and CLL (61–63, 92–94). One of the targets associated
with miR-155 is SHIP 1, a member of the inositol polyphosphate-
5-phosphatase family (63, 94). As SHIP 1 is a negative regulator
of AKT, suppression of the phosphatase would result in activation
of AKT. As miR-155 has been shown to be a prognostic factor
for cytogenetic normal AML patients (62), it would be plausible
that miR-155 suppression of SHIP 1 could promote signaling in
patients that would likely lack activating mutations. Interestingly,
miR-155 has now been shown to target B56α (76). Thus, we have
another layer of complexity in the putative miR/PP2A regulatory
axis to control AKT in leukemia cells. A hypothetical model is
depicted in Figure 2. Though quite complex, the possible feedback
regulatory mechanism could be necessary for controlling cell fate
and dysregulation could ultimately contribute to leukemogenesis
and/or drug resistance.
PP2A, miRs, AND CANCER STEM CELLS
A study by Yoon and colleagues using human embryonic stem
cells (hESC) demonstrated that (a) PP2A activity increases with
concomitant increase in A and C subunit expression in differenti-
ating hESC, (b) introduction of catalytic C subunit into hESC or
activation of PP2A using C2-ceramide was shown to induce hESC
differentiation, (c) hESC self-renewal is maintained in the pres-
ence of the PP2A inhibitor okadaic acid, and (d) suppression of
PP2A C subunit expression by siRNA-induced stem cell genes such
as OCT-4 and Nanog (95). The study found that stabilization of
MYC and activation of AKT was important in maintenance of the
hESC. Considering the importance of MYC (96) and AKT (30, 31)
in leukemic stem cells, it is plausible that PP2A regulation of both
these molecules is important in maintenance of leukemia stem cells
(LSC). At present, it is unknown if miRs play a role in regulating
PP2A activity in normal or cancer stem cells. An interesting possi-
bility emerges that the Cα subunit of PP2A and miR-520h could be
involved in this process. Su and colleagues recently demonstrated
that miR-520h suppression of the PP2A C α subunit was critical
for promoting tumor survival and metastasis of breast cancer and
cervical cancer cells (69, 70). The adenovirus type 5 E1A protein
was found to act as a tumor suppressor by inhibiting miR-520h
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FIGURE 1 | miR regulation of PP2A and PP2A inhibitors. Depicted in the figure are identified miRs that target the PP2A catalytic core subunits A and C,
various regulatory B subunits, and cellular inhibitors SET and CIP2A.
expression which resulted in activation of PP2A to suppress pro-
survival functions of NF κB and TWIST. Interestingly, a recent
analysis of miR expression in hESC cell lines indicated that mem-
bers of the miR-520 family were highly expressed in those cells
(97). While it remains to be determined, it is plausible that sup-
pression of PP2A in stem cells observed by Yoon and colleagues
could be due to suppression of PP2A by miR-520h (95). As this miR
targets a critical component of the catalytic core (i.e., C α) this miR
could potentially suppress any number of PP2A isoforms. Another
interesting possibility involves miR-200c and the PP2A A β sub-
unit. Recent studies have suggested that miR-200 family members
are critical for maintaining stem cells [reviewed in Ref. (97–99)].
These miRs are positively regulated by MYC, OCT-4, and other
stem cell transcription factors (98). The miR-200 c family mem-
ber was found to suppress the PP2A A β subunit in esophageal
cancer, resulting in increased chemoresistance and induction of
AKT (71). Considering the important role AKT plays in stem cells,
the suppression of this PP2A subunit could be important in sup-
porting cancer stem cells. Furthermore, blockade of one of the
PP2A A scaffold subunits by a miR could be another means for
suppression of PP2A function by a diverse number of PP2A iso-
forms. Supporting such a concept, recent work from the Perrotti
group has demonstrated that activation of PP2A using FTY-720
in CML cells results in eradication of the leukemic stem cells thus
the concept of PP2A regulation of stemness likely is pertinent to
LSC as well (100). The role of miRs in stem cell differentiation is
an active area of research but the field is just emerging. It remains
to be determined if and how miRs and PP2A might interact to
influence stem cell properties.
B55α REGULATION OF miRs IN LEUKEMIA
We recently identified a number of miRs that were subject to reg-
ulation by the B55α subunit that has been found to suppress AKT
and PKC α survival signaling in AML cells (37, 38). The possible
role of B55α in regulating miR expression was examined as we
had shown the B subunit indirectly supported expression of MYC
(38). MYC is known to control a number of miRs (47, 101–103).
Suppression of B55α by shRNA in the AML cell line OCI-AML3
resulted in altered expression of a number of miRs. For the most
part, reduction of the B subunit led to significant suppression (i.e.,
>2 fold) of over 30 miRs. This finding would be consistent with
possible participation of MYC as MYC has been suggested to have
a role in global repression of miRs (47). The miR most affected was
miR-1260a, though not much is known about this miR. Among
the other miRs that were suppressed are miR-142-3p, miR-142-5p,
and miR-195-5p (38). The miR-142 members have been shown to
be mutated in lymphoma and AML and thus are of interest to
those studying hematologic malignancies (103, 104). Relevant for
myeloid leukemia, miR-142-3p has been implicated in control of
myeloid differentiation (83). With MYC reduction in the AML
cells with reduced B55α, expression of the more prominent MYC
targets including those in miR 17–92 cluster were not strongly
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FIGURE 2 | Model of feedback loop in B56α/AKT/MYC axis involving
miRs. Model is presented where the B56α PP2A subunit and PTEN are
negatively regulated by miR-155. The miR may act as a rheostat for AKT
signaling as one the one hand PTEN suppression activates AKT but the
miR also suppresses the B subunit which is positively regulated by AKT.
The B subunit negatively regulates MYC and MYC supports expression of
AKT targeting miR-29 so another layer of feedback may exist via
MYC/miR-29.
FIGURE 3 | Model of effect of B55α/B56α competition on miR
expression. Model is presented where the B55α and B56α PP2A subunits
compete, resulting in additional regulation mediated by miRs. B55α
supports miR-155 which targets B56α so an additional level of suppression
exists in the competition between the two B subunits. B56α may have
pro-survival function by suppressing B55α mediated expression of
miR-191 and/or allowing expression of the miR-142 members, which are
inhibited by B55α.
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affected (38). However, induction of miR-195 observed in the cells
could be mediated by MYC. MYC has been shown to regulate a
number of miRs including miR-195 and it has been suggested that
repression of anti-tumor miRs may be critical to MYC’s onco-
genic activity (47). While it is not clear the role of miR-195 in
leukemia, the miR has been implicated as a tumor suppressor in a
number of solid tumor models (105). Targets of miR-195 include
cyclins and cyclin dependent kinases (106), MYB (107), and NF
κB signaling via IKKα and TAB3 (108). One of the miR-195 tar-
gets is the RET tyrosine kinase so perhaps inhibition of this kinase
may be important in leukemia (109). Of the miRs elevated in
response to suppression of B55α in the AML cells was miR-191-5p
and miR-155 (38). The miR-191-5p has been implicated as being
detrimental for patient survival in AML (89). As discussed earlier,
a critical miR in leukemia and other cancers is miR-155. Inter-
estingly, miR-155 has been shown to target B56α in macrophages
(76). This finding and the possibility that B55α supports miR-155
expression suggests a complex regulatory mechanism whereby the
B55 subunit can suppress the B56 subunit by competition for the
catalytic core and by inducing a miR that targets that competing B
subunit (depicted in Figure 3). This regulatory model is currently
under investigation in our laboratory.
CONCLUSION
The role of miRs as regulators of PP2A and possible control of miR
expression by PP2A isoforms is only just emerging. Publications
covering miR control of PP2A subunits and regulators of PP2A
(e.g., SET and CIP2A) are just emerging. Recent studies suggest
that miR control of the PP2A genes is important as results indicate
that dysregulation of PP2A targeting miRs can result in induction
of signaling pathways associated with the particular PP2A iso-
form. An example of such a finding involves activation of AKT
when miR-222 (which targets the B55α subunit) is elevated (72).
The recent finding that miR-155 target genes include a PP2A sub-
unit [i.e., B56α; Ref. (76)] raises the possibility that part of the
tumor support properties of this miR may involve suppression of
the B subunit. A link between miR-155 and B56α in leukemia cells
remains to be established. Surprisingly, the regulation of miRs by
PP2A has been less well studied. The well documented relationship
between MYC and PP2A would suggest that there would be PP2A
regulation of at least MYC sensitive miRs. Interestingly, though
B55α serves to positively support MYC expression, there were no
effects observed on MYC sensitive miRs in our recent study in AML
(38). Still other miRs including miR-142, miR-191, and miR-155
appear to be controlled by the PP2A subunit (38). It remains to
be seen how the B subunit regulates these miRs. Are specific tran-
scription factors targeted or are effects mediated by suppression of
kinases that phosphorylate transcription factors? Also, a role for
other PP2A B subunits in miR regulation is presently unknown. It
is likely that other B subunits will exert effects on miR expression
and warrant investigation. A better understanding of how PP2A
controls miRs and vice versa will provide a better understanding
how survival signaling is dysregulated in leukemia and may lead
to novel strategies for future therapies.
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